List of projects by:
Search by keyword:

Financed projects

Found 12 Results
Page 1 of 1

*SYLVAIN MARTEL

Magnetically Guided Bacteria to Specifically Deliver Anti-Cancer Agents to Colorectal Cancer Sites


Challenge: Many cancers are treated with cocktails of chemotherapeutic drugs designed to prevent growth and spread of cancerous cells. Chemotherapy damages healthy cells, causing undesired side effects such as myelosuppression and cardiotoxicity. Localized drug therapy, if appropriately delivered could have a major impact on quality of life and treatment efficacy. Solution: The lead investigator has pioneered a revolutionary drug delivery … Read More

Wednesday September 12th, 2018


*MICHEL BOUVIER

New GPCR-Specific Biosensor Technology to Monitor Cellular Events Associated with Drugs Efficacy and Side Effects


Challenge: G protein-coupled receptors (GPCRs) form the largest family of cell surface receptors involved in signal transduction of many hormones and transmitters. It follows that drugs targeting GPCRs represent close to 40% of all drugs on the market today. Recent discoveries regarding their function and mechanism of action help pave the way for the development of more selective therapeutics for … Read More

Tuesday September 11th, 2018


MORAG PARK

Integrated tumour-microenvironment biomarkers for improved targeting of breast cancer therapy


  Competition: FOCUS Program 2011 Funding: $1,300,0003 years Début : September 2011 The aim of this project is to develop enabling tools for better stratification of breast cancer patients by integrating information from the tumor and the surrounding stromal tissu. This will allow the development of personalized therapies relevant to specific tumor subtypes. The genetic heterogeneity of breast cancer tumors … Read More


*GORDON SHORE

Integrated platform to identify synthetic lethality opportunities in cancer therapy


  Competition: FOCUS Program 2010 Funding: $2,000,000 / 3 years Beginning: Septembre 2010 (COMPLETED PROJECT) The proposed platform will allow the identification of cellular pathways and gene targets acting in synergy with new or existing drugs for cancer therapy. This platform could also generate novel biomarkers to predict treatment response through personalized medicine. In recent years, only 8% of new … Read More


*MICHEL MAZIADE

Non-Invasive Diagnostic Test Using Electroretinography for Profiling Patients with Schizophrenia and Bipolar Disorders


Challenge: Psychiatric disorders such as schizophrenia, bipolar disorder and major depression affect 25 million of individuals in North America. Early identification of risk factors for people with genetic predispositions remains the most promising avenue for improving the treatments for these diseases. However, there are multiple subgroups of patients within a specific disease whose condition is mediated by different molecular pathologies, … Read More

Monday September 10th, 2018


RICHARD HOGE

Quantitative O2 MRI: a new window on mitochondrial dysfunction in Alzheimer’s Disease


  Competition: FOCUS Program 2012 Funding: $1,500,000 / 3 years Beginning: September 2012 Dr Hoge’s team has developed a new MRI-based method (QUO2 MRI) for non-invasive imaging of oxidative metabolism in the human brain. The objective of this project is therefore to optimize the method in Alzheimer’s disease patients to characterize mitochondrial dysfunction hypothesized to be a contributing factor in … Read More


*JOCELYN DUPUIS

PulmoBind: A New Non-Invasive Marker for the Early Diagnosis of Patients with Pulmonary Hypertension


Challenge: Pulmonary hypertension (PH) is a condition associated with loss of blood vessels in the lungs leading to a gradual increase in shortness of breath and substantial disability and mortality. The development of effective drugs is impeded by the lack of non-invasive tests to detect the disease at an early stage and to follow its progression. Solution: The goal of … Read More

Friday September 7th, 2018


*LOUIS-PHILIPPE VÉZINA

VLPExpress®: Novel high-throughput discovery platform to accelerate the development of new vaccines based on Virus-Like Particles


Challenge: Despite the enormous benefits that traditional vaccines have brought to human health in the last century, preventable diseases continue to claim millions of lives each year. New vaccine technologies that offer speed and versatility in production would have significant impact. The emergence of technologies based on Virus-Like Particles (VLPs) has paved the way for a new generation of vaccines … Read More


*MATTHIAS GÖTTE

A novel phage-based screening technology for antiviral


Challenge: Infection with herpes viruses is associated with several immunodeficient human diseases including the development of cancers. Patients receiving organ transplants are particularly sensitive to such infections. These patients are treated with antiviral agents; however, approved drugs are often associated with severe side effects and the development of resistance can compromise therapy. There is thus an urgent need to discover … Read More


*MICHEL BERGERON

Selectomics to monitor and predict the emergence of resistance to antibiotics


  Competition: Programme FOCUS 2011 Funding: $2,000,000 / 3 years Beginning: September 2011 (COMPLETED PROJECT) In the search for causes of the major problem of bacterial resistance to antibiotic drugs, look no further than your own intestinal tract. Researchers are exploring the complex microbial ecosystem of this part of the human body, which could harbor many of the genes that … Read More


JACQUES CORBEIL

Computational and machine learning approaches to improve design and screening of high bioactivity peptides for drug discovery


Competition: Programme FOCUS 2014 Funding: $1,600,000 / 3 years Beginning: December 2014 The cost of developing new drugs is now widely acknowledged by industry leaders as prohibitive, with some estimates now in excess of $ 5B per drug. It is imperative that new approaches are developed to mitigate the cost and time required to bring new drugs to market. To … Read More

Thursday September 6th, 2018


*EUSTACHE PARAMITHIOTIS

Development of biomarkers for measurement of early stage diabetes disease and for prediction of response to therapy


Competition: FOCUS Program 2009 Funding: $2,360,000 / 3 years  Beginning: September 2014 (COMPLETED PROJECT) Relying on Caprion’s CellCarta proteomics technology to develop panels of protein diabetes biomarkers, this project will improve early diagnosis and monitor disease progression, as well as, evaluate therapeutic response. Overview A unique panel of clinically validated pancreatic ß-cell biomarkers readily detected in blood were discovered which … Read More

Monday July 9th, 2018


Page 1 of 1